These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 21947546)

  • 21. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.
    Cheng H; Lear-Rooney CM; Johansen L; Varhegyi E; Chen ZW; Olinger GG; Rong L
    J Virol; 2015 Oct; 89(19):9932-8. PubMed ID: 26202243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening.
    Towner JS; Paragas J; Dover JE; Gupta M; Goldsmith CS; Huggins JW; Nichol ST
    Virology; 2005 Feb; 332(1):20-7. PubMed ID: 15661137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo.
    Ma J; Zhang X; Soloveva V; Warren T; Guo F; Wu S; Lu H; Guo J; Su Q; Shen H; Solon E; Comunale MA; Mehta A; Guo JT; Bavari S; Du Y; Block TM; Chang J
    Antiviral Res; 2018 Feb; 150():112-122. PubMed ID: 29253498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model.
    Smither SJ; Eastaugh LS; Steward JA; Nelson M; Lenk RP; Lever MS
    Antiviral Res; 2014 Apr; 104():153-5. PubMed ID: 24462697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus.
    Andersen KG; Shapiro BJ; Matranga CB; Sealfon R; Lin AE; Moses LM; Folarin OA; Goba A; Odia I; Ehiane PE; Momoh M; England EM; Winnicki S; Branco LM; Gire SK; Phelan E; Tariyal R; Tewhey R; Omoniwa O; Fullah M; Fonnie R; Fonnie M; Kanneh L; Jalloh S; Gbakie M; Saffa S; Karbo K; Gladden AD; Qu J; Stremlau M; Nekoui M; Finucane HK; Tabrizi S; Vitti JJ; Birren B; Fitzgerald M; McCowan C; Ireland A; Berlin AM; Bochicchio J; Tazon-Vega B; Lennon NJ; Ryan EM; Bjornson Z; Milner DA; Lukens AK; Broodie N; Rowland M; Heinrich M; Akdag M; Schieffelin JS; Levy D; Akpan H; Bausch DG; Rubins K; McCormick JB; Lander ES; Günther S; Hensley L; Okogbenin S; ; Schaffner SF; Okokhere PO; Khan SH; Grant DS; Akpede GO; Asogun DA; Gnirke A; Levin JZ; Happi CT; Garry RF; Sabeti PC
    Cell; 2015 Aug; 162(4):738-50. PubMed ID: 26276630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Viral hemorrhagic fevers--Ebola hemorrhagic fever, Marburg virus disease, and Lassa fever].
    Taniguchi K
    Nihon Naika Gakkai Zasshi; 2004 Nov; 93(11):2303-8. PubMed ID: 15624463
    [No Abstract]   [Full Text] [Related]  

  • 27. Identification of a clinical compound losmapimod that blocks Lassa virus entry.
    Zhang X; Yan F; Tang K; Chen Q; Guo J; Zhu W; He S; Banadyga L; Qiu X; Guo Y
    Antiviral Res; 2019 Jul; 167():68-77. PubMed ID: 30953674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of therapeutics for treatment of Ebola virus infection.
    Li H; Ying T; Yu F; Lu L; Jiang S
    Microbes Infect; 2015 Feb; 17(2):109-17. PubMed ID: 25498866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deployable CRISPR-Cas13a diagnostic tools to detect and report Ebola and Lassa virus cases in real-time.
    Barnes KG; Lachenauer AE; Nitido A; Siddiqui S; Gross R; Beitzel B; Siddle KJ; Freije CA; Dighero-Kemp B; Mehta SB; Carter A; Uwanibe J; Ajogbasile F; Olumade T; Odia I; Sandi JD; Momoh M; Metsky HC; Boehm CK; Lin AE; Kemball M; Park DJ; Branco L; Boisen M; Sullivan B; Amare MF; Tiamiyu AB; Parker ZF; Iroezindu M; Grant DS; Modjarrad K; Myhrvold C; Garry RF; Palacios G; Hensley LE; Schaffner SF; Happi CT; Colubri A; Sabeti PC
    Nat Commun; 2020 Aug; 11(1):4131. PubMed ID: 32807807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genistein treatment of cells inhibits arenavirus infection.
    Vela EM; Bowick GC; Herzog NK; Aronson JF
    Antiviral Res; 2008 Feb; 77(2):153-6. PubMed ID: 17961732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions.
    Bausch DG; Sprecher AG; Jeffs B; Boumandouki P
    Antiviral Res; 2008 Apr; 78(1):150-61. PubMed ID: 18336927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins.
    Barrientos LG; Lasala F; Otero JR; Sanchez A; Delgado R
    J Infect Dis; 2004 Apr; 189(8):1440-3. PubMed ID: 15073681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model.
    Huggins J; Zhang ZX; Bray M
    J Infect Dis; 1999 Feb; 179 Suppl 1():S240-7. PubMed ID: 9988190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A potent Lassa virus antiviral targets an arenavirus virulence determinant.
    Madu IG; Files M; Gharaibeh DN; Moore AL; Jung KH; Gowen BB; Dai D; Jones KF; Tyavanagimatt SR; Burgeson JR; Korth MJ; Bedard KM; Iadonato SP; Amberg SM
    PLoS Pathog; 2018 Dec; 14(12):e1007439. PubMed ID: 30576397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methanol Fixation, but not Giemsa Staining, Inactivates Ebola and Lassa Viruses in Peripheral Blood Smears Made on Plastic Microscope Slides.
    Relich RF; Feldmann H; Haddock E
    Am J Trop Med Hyg; 2020 Nov; 103(5):2085-2090. PubMed ID: 32959767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genistein, a general kinase inhibitor, as a potential antiviral for arenaviral hemorrhagic fever as described in the Pirital virus-Syrian golden hamster model.
    Vela EM; Knostman KA; Mott JM; Warren RL; Garver JN; Vela LJ; Stammen RL
    Antiviral Res; 2010 Sep; 87(3):318-28. PubMed ID: 20600333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers.
    Warfield KL; Swenson DL; Olinger GG; Nichols DK; Pratt WD; Blouch R; Stein DA; Aman MJ; Iversen PL; Bavari S
    PLoS Pathog; 2006 Jan; 2(1):e1. PubMed ID: 16415982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HSPA5 is an essential host factor for Ebola virus infection.
    Reid SP; Shurtleff AC; Costantino JA; Tritsch SR; Retterer C; Spurgers KB; Bavari S
    Antiviral Res; 2014 Sep; 109():171-4. PubMed ID: 25017472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inactivation Validation of Ebola, Marburg, and Lassa Viruses in AVL and Ethanol-Treated Viral Cultures.
    Cutts T; Leung A; Banadyga L; Krishnan J
    Viruses; 2024 Aug; 16(9):. PubMed ID: 39339831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CP100356 Hydrochloride, a P-Glycoprotein Inhibitor, Inhibits Lassa Virus Entry: Implication of a Candidate Pan-Mammarenavirus Entry Inhibitor.
    Takenaga T; Zhang Z; Muramoto Y; Fehling SK; Hirabayashi A; Takamatsu Y; Kajikawa J; Miyamoto S; Nakano M; Urata S; Groseth A; Strecker T; Noda T
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.